Latest Conference

The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.

Advanced age and comorbidities were more accurate predictors of severe COVID-19 disease than innate immune response.

Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.

A study presented at the SHEA 2022 conference determined how common and severe breakthrough infections were for Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccine recipients.

A survey’s results show updating programs is largely dependent on resources and dedicated personnel.

An examination of COVID-19 infections by occupation found that most cases occurred in people who worked in management and healthcare, and COVID-19 death rates were highest among building/grounds cleaning and maintenance employees.

A study found that hospital providers who prescribe unnecessarily high rates of antibiotics are likely to continue doing so over time.

A large veterans health administration study estimated antibiotic use during the last 6 months of life for patients under hospice or palliative care.

During the COVID-19 pandemic, use of community-acquired pneumonia antibiotics increased significantly, while relative utilization of carbapenems decreased.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.

Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.

Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.

Investigators found a couple of different factors for this phenomenon.

In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

One study presented at CROI 2022 found that HIV PrEP awareness increased among Latinx/Hispanic men who have sex with men, but usage has remained relatively stable for several years.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

Dr. Nicola Petrosillo discusses treating C difficile infection and maintaining antimicrobial stewardship during the height of the COVID-19 pandemic in Italy.

Antimicrobial resistance is a growing problem that requires international collaboration to educate the general public and stakeholders, while simultaneously developing solutions.

Highlights from the sessions of the World Anti-Microbial Resistance Congress 2021 included addressing the global threat for AMR and looking at real world data and real world evidence to deter resistance.

Anti-microbial resistance is one of the most critical issues in healthcare, and the CDC and WHO addressed these concerns with plans to fight back against AMR at the annual world congress.